Chronic HBV Carrier’s acceptance of regular surveilling program in China

Abstract

Long-term compliance with regular surveillance is important for the prevention and timely management of chronic hepatitis B (CHB). However, there are no researches focusing on the compliance of hepatitis B virus infected patients in regular surveillance so far. The purpose of our study was to investigate the outpatient compliance with long-term regular surveillance in China. Data of 3257 CHB outpatients was pooled and analyzed to assess the outpatient’s compliance with the long-term regular surveillance plan. In all outpatients, the non-follow-up and the follow-up group accounted for 73.2% and 26.8%, respectively. Among the follow-up outpatient’s, only 48.9% received ongoing-follow-up and 51.1% were finally lost to follow-up; the median length of visiting duration was 25 months; and the predictive 1-, 2-, 3-, 4- and 5-year ongoing follow-up rate was 72.7%, 52.5%, 42.4%, 33.8%, and 26.3%, respectively. In conclusion, our survey proved that the regular long-term surveillance on Chinese chronic HBV carrier is difficult to be fully implemented. A large proportion of outpatients do not receive routine follow-up and are at risk of treatment delay due to various social reasons.

Keywords

hepatitis B virus / compliance / follow-up / outpatient

References

[1] GanemD, PrinceAM. Hepatitis B virus infection-natural history and clinical consequences. N Engl J Med, 2004, 350(11): 1118-1129

[2] LiuJ, FanDM. Hepatitis B in China. Lancet, 2007, 369(9573): 1582-1583

[3] LiangXF, ChenYS, WangXJ, et al.. A study on the sero-epidemiology of hepatitis B in Chinese population aged over 3-years old: the report from Chinese Center for Disease Control and Prevention. Zhonghua Liu Xing Bing Xue Za Zhi (Chinese), 2005, 26(9): 655-658

[4] CuiFQ, WangXJ, LiangXF. Epidemiological analysis on reported hepatitis B under 15 years in China: the report from Chinese Center for Disease Control and Prevention. Zhongguo Yi miao He Mianyi Za Zhi (Chinese), 2006, 12(3): 206-208

[5] LinSY, ChangET, SoSK. Why we should routinely screen Asian American adults for hepatitis B: a cross sectional study of Asians in California. Hepatology, 2007, 46(4): 1034-1040

[6] WaiCT, MakB, ChuaW, et al.. The majority of hepatitis B carriers are not on regular surveillance in Singapore. Singapore Med J, 2004, 45(9): 423-426

[7] LokAS. The maze of treatments for hepatitis B. N Engl J Med, 2005, 352(26): 2743-2746

[8] HadziyannisSJ, TassopoulosNC, HeathcoteEJ, et al.. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med, 2005, 352(26): 2673-2681

[9] McMahonBJ, BulkowL, HarpsterA, et al.. Screening for hepatocellular carcinoma in Alaska natives infected with chronic hepatitis B: A 16-year population-based study. Hepatology, 2000, 32(4Pt1): 842-846

[10] Chinese Society of HepatologyChinese Society of Infectious Diseases, Chinese Medical Association.. The guideline of prevention and treatment for chronic hepatitis B (2010 version). Zhongguo Bing Du Xue Za Zhi (Chinese), 2011, 1(1): 9-22

[11] LokAS, McMahonBJ. Chronic hepatitis B: update 2009. Hepatology, 2009, 50(3): 661-662

[12] European Association for the Study of the Liver.. EASL Clinical Practice Guidelines: Management of Chronic Hepatitis B. J Hepatol, 2009, 50(2): 227-242

[13] LiawYF, LeungN, KaoJH, et al.. Asian-Pacific Consensus Statement on the Management of Chronic Hepatitis B: a 2008 Update. Hepatol Int, 2008, 2(3): 263-283

[14] ShermanM, ShafranS, BurakK, et al.. CANADIAN CONSENSUS GUIDELINES Management of chronic hepatitis B: Consensus guidelines. Can J Gastroenterol, 2007, 21(SupplC): 5-24

[15] VeldhuijzenIK, ToyM, HahneSKM, et al.. Screening and early treatment of migrants for chronic hepatitis B virus infection is cost-effective. Gastroenterology, 2006, 138(2): 522-530

[16] PawlotskyJM, DusheikoG, HatzakisA, et al.. Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: Recommendations for a standardized approach. Gastroenterology, 2008, 134(2): 405-415

[17] GianniniEG, TorreF, BassoM, et al.. A significant proportion of patients with chronic hepatitis B who are candidates for antiviral treatment are untreated: A region-wide survey in Italy. J Clin Gastroenterol, 2009, 43(10): 1001-1007

[18] JungCW, TanJ, TanN, et al.. Evidence for the insufficient evaluation and undertreatment of chronic hepatitis B infection in a predominantly low-income and immigrant population. J Gastroenterol Hepatol, 2010, 25(2): 369-375

[19] CohenC, HolmbergSD, McMahonBJ, et al.. Is chronic hepatitis B being undertreated in the United States?. J Viral Hepat, 2011, 18(6): 377-383

[20] LuFM, ZhuangH. Management of hepatitis B in China. Chin Med J (Engl), 2009, 122(1): 3-4

[21] FangQ, HaoYH, LiL, et al.. Primary construction of the electronic medical records for patients with liver diseases. Yi Xue Yu She Hui (Chinese), 2012, 25(4): 29-31

[22] FangQ, LiL, ZhangZH, et al.. Analysis of the constituent ratio and its clinical diagnostic subtypes for patients with chronic HBsAg infection in their first outpatient visit. Nei Ke Ji Wei Zhong Zhen Yi Xue Za Zhi (Chinese), 2012, 18(2): 98-101

[23] ChaoJ, ChangET, SoSKS. Hepatitis B and liver cancer knowledge and practices among healthcare and public health professionals in China: a cross-sectional study. BMC Public Health, 2010, 10: 98

[24] BlumenthalD, HsiaoW. Privatization and its discontents—the evolving Chinese health care system. N Engl J Med, 2005, 353(11): 1165-1170

[25] DongN, HeB, ZhuangH. An online questionnaire survey on awareness of antiviral treatment in patients with chronic hepatitis B. Chin Hepatol, 2009, 14(1): 8-10